ArticleCancer medicine2024

Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.

Guido Giordano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.